Rossello, Xavier http://orcid.org/0000-0001-6783-8463
Ariti, Cono
Pocock, Stuart J.
Ferreira, João Pedro
Girerd, Nicolas
McMurray, John J. V.
Van Veldhuisen, Dirk J.
Pitt, Bertram
Zannad, Faiez
Funding for this research was provided by:
Sociedad Española de Cardiología (SEC-CNIC CARDIOJOVEN Program)
Article History
Received: 31 August 2018
Accepted: 24 September 2018
First Online: 27 September 2018
Compliance with ethical standards
:
: XR, CA, SJP, and DJVV have nothing to declare. JMcM reports conflicts of interest from Roche Pharmaceuticals, during the conduct of the study; other from Novartis, Cardiorentis, Amgen Oxford University/Bayer, GlaxoSmithKline, Theracos, Abbvie, DalCor, Pfizer, Merck, AstraZeneca Bristol Myers Squibb (BMS), Kidney Research UK (KRUK)/Kings College Hospital, London/Vifor-Fresenius Pharma, outside the submitted work. BP reports personal fees from Bayer, personal fees from KDP pharmaceuticals, and personal fees from Astrazeneca, outside the submitted work; In addition, BP has a patent site-specific delivery of eplerenone to the myocardium pending to university of Michigan. Faiez Zannad received honoraria and/or travel fees for participation in clinical trial committees and meetings/presentations from Amgen, AstraZeneca, Bayer, Boehringer, Boston Scientific, GE Healthcare, CVRx, Relypsa/Vifor-Fresenius, J&J, Pfizer, Novartis, Quantum Genomics, Resmed, Takeda, and received honoraria and/or travel fees for participation in advisory boards from BMS, KBP BioSciences, Livanova, NovoNordisk, Roche, ZS Pharma.